Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$0.92 USD

0.92
33,643

+0.03 (3.67%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $0.91 -0.01 (-0.64%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DRRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

DURECT Corporation [DRRX]

Reports for Purchase

Showing records 41 - 60 ( 140 total )

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 41

09/24/2020

Daily Note

Pages: 4

Phase 2b AH Trial Designed to Support Full Approval; Phase 2 COVID-19 Trial Has Strong Rationale Too; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 42

08/26/2020

Industry Report

Pages: 9

EASL 2020 Virtual Meeting Overview and Planner

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 43

08/04/2020

Company Report

Pages: 6

2Q20 Results; AVB-500 Moves Forward in PROC and ccRCC on Solid Footing

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 44

07/01/2020

Daily Note

Pages: 3

DURECT Kicks off DUR-928 Study in COVID-19 Patients With Acute Liver or Kidney Injury; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ABBOTT G

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 45

06/29/2020

Company Report

Pages: 4

The End of the Gilead Agreement Has No Impact on Our Model or Thesis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 46

05/27/2020

Company Report

Pages: 7

We View Positive Phase 1b NASH Data as Highly Supportive of Advancing Development; Rais

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 47

05/12/2020

Company Report

Pages: 8

1Q20 Recap: DUR-928 Takes on COVID-19; Phase 2 Data Potentially by YE20; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 48

03/04/2020

Company Report

Pages: 6

4Q19 Recap Expecting an Eventful Mid-2020 for DUR-928 in AH and NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 49

01/03/2020

Company Report

Pages: 7

Psoriasis Failure a Non-Event; We Raise PT to $5.50 on Updated AH Model

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 50

11/25/2019

Daily Note

Pages: 9

Taking a Closer Look at the Striking Results of DUR-928 in Alcoholic Hepatitis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 51

11/20/2019

Daily Note

Pages: 3

Expecting a Favorable Outcome From POSIMIR''s AdCom Meeting on January 16, 2020; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 52

11/05/2019

Company Report

Pages: 8

3Q Recap: DUR-928 Offers Breakthrough Data for Alcoholic Hepatitis

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 53

10/15/2019

Industry Report

Pages: 49

Final Program for Our Third Annual NASH Investor Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 54

10/07/2019

Industry Report

Pages: 48

Program for Our Third Annual NASH Investor Conference, October 21, New York

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 100.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 55

09/18/2019

Daily Note

Pages: 3

Positive Data in Alcoholic Hepatitis Serve as First of Three Validation Points for DUR-928 in 2H19; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 56

09/10/2019

Daily Note

Pages: 3

Recently Signed Gilead Partnership Yields First $10M Milestone; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 57

08/19/2019

Company Report

Pages: 19

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 58

08/02/2019

Company Report

Pages: 9

2Q Recap: Four Potential Value Inflection Points in 2H19; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 59

07/22/2019

Daily Note

Pages: 4

Gilead License Agreement Brings Strong Validation and Economics; Focus Remains on DUR-928

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 60

07/19/2019

Company Report

Pages: 5

POSIMIR PDUFA December 27; 2H19 Readouts for DUR-928 May Represent Inflection Point; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party